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INTRODUCTION
  Gastroesophageal Reflux Disease (GERD) is one 
of the most common gastrointestinal diseases 
resulting in the backwash of gastric acid into the 
esophageal lumen. 
•  Proton pump inhibitors (PPI) are the mainstay of 
treatment of GERD; however, nearly 1/3 of patients 
have a suboptimal response to PPI therapy.
•  Patients refractory to PPI therapy are appropriate 
candidates for invasive interventions such as 
transoral incisionless fundoplication (TIF), which  
is gaining popularity as a minimally invasive, 
effective, and safe treatment option in GERD. 
METHODS 
•  IRB approved retrospective chart review of TIF 
procedures performed at a large care center 
with the primary objective of evaluating 
procedural data that includes technical and 
clinical success rates. Adverse events related  
to the procedure were also evaluated.
•  Clinical success rate was measured by a 
reduction in PPI or H2 Blockers (H2B) use,  
and evaluation of symptom resolution  
quantified by GERD health-related quality  
of life (HQRL) questionnaire. 
RESULTS 
•  18 patients underwent TIF (38.9%) or TIF with 
hiatal hernia repair (TIF+HHR, 61.1%). 
•  Technical success rate was 94.4% (TIF device 
was unable to be inserted even after esophageal 
dilation in one patient). 
•  After 12 months, 72.7% of patients who used 
PPI prior to TIF/HHR stopped using it completely, 
18.2% reduced the dose by at least 50%, and 
only 9.1% were unable to titrate the PPI down. 
Similar results were shown with H2B use as 
66.7% admitted stopping it entirely, and 33.3% 
were not able to reduce to dose. 
•  Mean value of the GERD HRQL score was  
25.13 prior to the procedure and decreased 
significantly within 6 and 12 months after TIF/
HHR (mean values 6.15 and 3.27, respectively). 
•  84.6% stated that they are satisfied with their 
condition 6 months after the procedure, and 
81.8% admitted being satisfied after a year,  
with the other 9.1% preferring to remain neutral 
regarding their symptoms. 
•  Adverse events occurred in two patients and  
were limited to mild self-resolving bleeding and 
superficial mucosal tear after esophageal dilation, 
which did not require any further intervention. 
CONCLUSION
•  Above data from our single-center retrospective 
study clearly demonstrates TIF as a safe and 
effective treatment option for refractory GERD 
with a high technical success rate of 94.4%  
and devoid of any major complications. 
•  Majority of the patients who underwent the 
procedure were able to stop taking their 
prescribed medications for GERD and  
reported significant or complete resolution  
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Mean value of GERD HRQL total points
Mean value of GERD HRQL Heartburn score
GERD HRQL total points prior to  
TIF/HHR
Min Max Mean StDev Sum
Percentile
0.05 0.10 0.25 0.50 
Median
0.75 0.90 .095
0.00 37.0 25.13 8.21 402.00 15.75 21.50 23.75 25.50 26.00 35.00 37.00
0 10 20 30 40
GERD HRQL total points 12 months 
after TIF/HHR
Min Max Mean StDev Sum
Percentile
0.05 0.10 0.25 0.50 
Median
0.75 0.90 .095
0.00 12.00 3.27 4.52 36.00 0 0.00 0.00 0.00 4.50 11.00 11.50
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